Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Join SI Premium – FREE
Marina Biotech, Inc. (Nasdaq: MRNA) reported Q1 loss of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $214 million versus the consensus estimate of $150 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) PT Raised to $90 at TD Cowen
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Danaher (DHR) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
